Plasminogen Activator Inhibitor-1 and Adiponectin Are Associated With Metabolic Syndrome Components. (15th September 2021)
- Record Type:
- Journal Article
- Title:
- Plasminogen Activator Inhibitor-1 and Adiponectin Are Associated With Metabolic Syndrome Components. (15th September 2021)
- Main Title:
- Plasminogen Activator Inhibitor-1 and Adiponectin Are Associated With Metabolic Syndrome Components
- Authors:
- Vecchiola, Andrea
García, Killén
González-Gómez, Luis M
Tapia-Castillo, Alejandra
Artigas, Rocío
Baudrand, René
Kalergis, Alexis M
Carvajal, Cristian A
Fardella, Carlos E - Abstract:
- Abstract: BACKGROUND: We aimed to study the associations of adipocytokines, endothelial damage markers, and high-sensitivity C-reactive protein (hs-CRP) with metabolic syndrome (MetS) components. METHODS: This cross-sectional study included 202 subjects categorized into MetS and No-MetS according to Harmonizing Adult Treatment Panel III. RESULTS: Subjects with MetS showed higher levels of proinflammatory molecules but significantly lower adiponectin levels than subjects with No-MetS. Among the studied adipocytokines, plasminogen activator inhibitor-1 (PAI-1) and adiponectin showed the strongest associations with most MetS components. PAI-1 was associated with MetS (odds ratio (OR) 1.107 (1.065–1.151), P < 0.0001), whereas adiponectin was inversely associated with MetS (OR 0.710 (0.610–0.825), P < 0.0001). Following adjustment by sex, age, body mass index, and 24-hour urinary sodium excretion in a multivariate analysis, the association of PAI-1 (OR 1.090 (1.044–1.137), P < 0.0001) and adiponectin (OR 0.634 (0.519–0.775), P < 0.0001) with MetS remained significant. Multivariate analyses supported a model in which systolic blood pressure (BP) could be predicted by PAI-1, hs-CRP, and matrix metalloproteinase 2 ( R 2 = 0.125; P = 0.04); diastolic BP ( R 2 = 0.218; P = 0.0001) and glucose ( R 2 = 0.074; P = 0.0001) could be predicted by PAI-1; waist circumference could be predicted by PAI-1 and hs-CRP ( R 2 = 0.28; P = 0.016). Receiver operating characteristic curve analysisAbstract: BACKGROUND: We aimed to study the associations of adipocytokines, endothelial damage markers, and high-sensitivity C-reactive protein (hs-CRP) with metabolic syndrome (MetS) components. METHODS: This cross-sectional study included 202 subjects categorized into MetS and No-MetS according to Harmonizing Adult Treatment Panel III. RESULTS: Subjects with MetS showed higher levels of proinflammatory molecules but significantly lower adiponectin levels than subjects with No-MetS. Among the studied adipocytokines, plasminogen activator inhibitor-1 (PAI-1) and adiponectin showed the strongest associations with most MetS components. PAI-1 was associated with MetS (odds ratio (OR) 1.107 (1.065–1.151), P < 0.0001), whereas adiponectin was inversely associated with MetS (OR 0.710 (0.610–0.825), P < 0.0001). Following adjustment by sex, age, body mass index, and 24-hour urinary sodium excretion in a multivariate analysis, the association of PAI-1 (OR 1.090 (1.044–1.137), P < 0.0001) and adiponectin (OR 0.634 (0.519–0.775), P < 0.0001) with MetS remained significant. Multivariate analyses supported a model in which systolic blood pressure (BP) could be predicted by PAI-1, hs-CRP, and matrix metalloproteinase 2 ( R 2 = 0.125; P = 0.04); diastolic BP ( R 2 = 0.218; P = 0.0001) and glucose ( R 2 = 0.074; P = 0.0001) could be predicted by PAI-1; waist circumference could be predicted by PAI-1 and hs-CRP ( R 2 = 0.28; P = 0.016). Receiver operating characteristic curve analysis showed that a PAI-1 concentration had the best sensitivity and specificity for discriminating subjects with MetS. CONCLUSION: PAI-1 and adiponectin rendered the most robust associations with MetS components in a general population, indicating that unfavorable adipose tissue performance is a key contributor to these metabolic anomalies. Further prospective analyses should allow establishing whether these adipocytokines can anticipate the progress of MetS and cardiovascular risk. … (more)
- Is Part Of:
- American journal of hypertension. Volume 35:Number 4(2022)
- Journal:
- American journal of hypertension
- Issue:
- Volume 35:Number 4(2022)
- Issue Display:
- Volume 35, Issue 4 (2022)
- Year:
- 2022
- Volume:
- 35
- Issue:
- 4
- Issue Sort Value:
- 2022-0035-0004-0000
- Page Start:
- 311
- Page End:
- 318
- Publication Date:
- 2021-09-15
- Subjects:
- adipokines -- blood pressure -- endothelial damage -- hypertension -- inflammation -- metabolic syndrome -- obesity
Hypertension -- Periodicals
616.132005 - Journal URLs:
- http://ajh.oxfordjournals.org/ ↗
http://www.nature.com/ajh/index.html ↗
http://ukcatalogue.oup.com/ ↗
http://www.sciencedirect.com/science/journal/08957061 ↗ - DOI:
- 10.1093/ajh/hpab138 ↗
- Languages:
- English
- ISSNs:
- 0895-7061
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0826.400000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21431.xml